HTG Molecular Diagnostics, Inc. has now expanded the potential markets and applications for its pioneering HTG Transcriptome Panel (HTP). Since launching HTP with commercial availability in the US and Europe in August 2021, HTG has completed validation of additional sample types that are more commonly used outside of oncology, and expanded sequencing capabilities to facilitate easier testing of larger sample cohorts. Initially validated for neoplastic tissue, HTG has now validated HTP for use with normal FFPE tissue and other non-neoplastic tissues. In addition, the panel has been validated with PAXgene, a popular liquid blood-based sample type, and with extracted RNA from both fresh frozen and FFPE tissue samples. In addition, to maximize sequencer flexibility, HTP is now validated across Illumina’s complete portfolio of production-scale sequencers including the NextSeq 500/550, NextSeq 1000/2000 and NovaSeq 6000 platforms. This will allow HTG’s customers to more efficiently sequence larger sample cohorts, which HTG believes will significantly increase the efficiency of data generation, in addition to reducing time to results and the overall cost of customer studies. Measuring approximately 20,000 mRNA targets using HTG’s proprietary HTG EdgeSeqTM technology, HTP can be deployed to profile a wide range of diseases, assist in identifying new drug candidates, develop molecular classification tools and discover critical biomarkers. HTG’s panel reduces sample amount requirements, is less sensitive to RNA degradation due to sample age, and provides faster turnaround times than other, currently available methods. HTP has also been shown to have a higher sample success rate than RNA-Seq for gene expression profiling. HTG previously released a series of White Papers highlighting these capabilities and performance measures. HTG expects to continue to provide additional internal and expected third party validation data for HTP in future periods.